<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">van der HEIJDE, DÉSIRÉE</style></author><author><style face="normal" font="default" size="100%">BREEDVELD, FERDINAND C.</style></author><author><style face="normal" font="default" size="100%">KAVANAUGH, ARTHUR</style></author><author><style face="normal" font="default" size="100%">KEYSTONE, EDWARD C.</style></author><author><style face="normal" font="default" size="100%">LANDEWÉ, ROBERT</style></author><author><style face="normal" font="default" size="100%">PATRA, KAUSHIK</style></author><author><style face="normal" font="default" size="100%">PANGAN, AILEEN L.</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Disease Activity, Physical Function, and Radiographic Progression After Longterm Therapy with Adalimumab Plus Methotrexate: 5-Year Results of PREMIER</style></title><secondary-title><style face="normal" font="default" size="100%">The Journal of Rheumatology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">2237-2246</style></pages><doi><style  face="normal" font="default" size="100%">10.3899/jrheum.100208</style></doi><volume><style face="normal" font="default" size="100%">37</style></volume><issue><style face="normal" font="default" size="100%">11</style></issue><abstract><style  face="normal" font="default" size="100%">Objective. To evaluate the efficacy and safety of initial combination treatment with adalimumab (ADA) and methotrexate (MTX) versus monotherapy with ADA or MTX during an open-label extension of PREMIER. Methods. Patients with early rheumatoid arthritis (RA) received blinded ADA plus MTX, ADA alone, or MTX alone for 2 years in PREMIER. At Year 2, patients could enroll in an open-label extension and receive ADA monotherapy; MTX could be added at the investigator’s discretion. Longterm efficacy results are presented as observed data. Results. In the open-label period, 497 of the original 799 randomized patients had ≥ 1 dose of ADA (by original randomization: ADA plus MTX, n = 183; ADA, n = 159; MTX, n = 155). In the completers cohort [patients with available Year-5 ACR responses and modified total Sharp scores (mTSS)], the Year-5 mean change from baseline in mTSS for the ADA+MTX arm (n = 124) was 2.9, compared with 8.7 and 9.7 in the ADA (n = 115) and MTX (n = 115) arms. Comprehensive disease remission, defined as the combination of DAS28 remission, normal function (Health Assessment Questionnaire ≤ 0.5), and radiographic nonprogression (ΔmTSS ≤ 0.5), was achieved by more patients in the initial ADA+MTX arm (35%) than in the ADA (13%) or MTX (14%) arms. Conclusion. Initial combination treatment with ADA plus MTX, followed by open-label ADA, led to better longterm clinical, functional, and radiographic outcomes than either initial ADA or MTX monotherapy during 5 years of treatment.</style></abstract></record></records></xml>